Kymera Investor Day Presentation Deck
Counts
150
100
50-
IFNy-dependent Gene Signature Induced by STAT3
Degrader Monotherapy in CT-26 Tumors
Infy
Vehicle
KTX-201
250
150-
100
50
0-
Stat1
HIH
Vehicle
STAT3 Degrader's Role in Immuno-Oncology:
Sensitization of Tumors to Anti PD-1
• STAT3 degradation
remodels the CT-26
TME to be more
immune-favorable
with upregulation of
anti-tumor
immunity genes
previously identified
as predictors of
clinical response to
pembrolizumab
in
KTX-201
2000
1500-
1000
500
0₁
Cxcl10
HA
Vehicle
KTX-201
4000
3000
IFN-Y
ID01
CXCL10
CXCL9
HLA-DRA
STAT1
IFNG
2000-
1000
Cxcl9
+To
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
Vehicle
CT-26: Veh or KTX-201 25 mg/kg q2D IP; n-6/grp; t = Day 11
KTX-201
Expression score
60 Ido1
2.8-
2.6-
2.4-
2.2-
2.0-
1.8-
1.6-
1.4-
1.2-
1.0-
0.8
40
IFN-y and Expanded Immune Gene Signature
B
Vehicle
Nonresponder
KTX-201
IFN-y signature
Responder
Source: Ayers et al., JCI, 2017
STAT3 Degradation and Anti-PD-1 Synergy
KTX-201
synergizes with
anti-PD-1
leading to 60%
complete
responses in CT-
26 model
Complete
responders reject
tumor
rechallenge
demonstrating
development of
long-term
immune memory
Combination
extends survival
KYMERA R&D DAY - December 16th, 2021
Tumor Volume (mm³)
Tumor Volume (mm³)
% Remaining on Study
5000
4000
3000
2000
1000
0
5000
4000
3000
2000
1000
100
80
60-
0
40-
20
0
0
7
20
20
Days
Days
14
40
Anti-PD1
n=10
Vehicle 2000
n=10
1/10 CRs
40
21
28
5000
60
4000
3000
1000
0
5000
4000
3000
2000
1000
35
0
0
0
42
Day Post Tumor Implant
20
20
49
KTX-201
n=10
T
56
40
Days
Combination
n=10
6/10 CRs
CT-26 rechallenge
60
40
Days
63
60
80
Vehicle
KTX-201
Anti-PD1
Combination
PAGE 63View entire presentation